Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

biomarin pharmaceutical inc. - BMRN

BMRN

Close Chg Chg %
63.45 0.81 1.28%

Closed Market

64.26

+0.81 (1.28%)

Volume: 1.30M

Last Updated:

Nov 22, 2024, 4:00 PM EDT

Trade Now

Company Overview: biomarin pharmaceutical inc. - BMRN

BMRN Key Data

Open

$63.88

 Day Range

63.78 - 64.46

52 Week Range

61.15 - 99.55

 Market Cap

N/A

Shares Outstanding

NaN

 Public Float

188.20M

Beta

N/A

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

N/A

Yield

N/A

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.56M

  

BMRN Performance

1 Week
 
 1.32%
 
1 Month
 
 -7.84%
 
3 Months
 
 -28.62%
 
1 Year
 
 -27.13%
 
5 Years
 
 -17.37%
 

BMRN Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 30
Full Ratings ➔

About biomarin pharmaceutical inc. - BMRN

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.

BMRN At a Glance

BioMarin Pharmaceutical, Inc.
770 Lindaro Street
San Rafael, California 94901
Phone 1-415-506-6700 Revenue 2.42B
Industry Biotechnology Net Income 167.65M
Sector Health Technology 2023 Sales Growth 18.164%
Fiscal Year-end 12 / 2024 Employees 3,401
View SEC Filings

BMRN Valuation

P/E Current 38.205
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 110.194
Price to Sales Ratio 7.636
Price to Book Ratio 3.673
Price to Cash Flow Ratio 115.997
Enterprise Value to EBITDA 62.022
Enterprise Value to Sales 7.66
Total Debt to Enterprise Value 0.061

BMRN Efficiency

Revenue/Employee 711,382.535
Income Per Employee 49,292.855
Receivables Turnover 3.818
Total Asset Turnover 0.366

BMRN Liquidity

Current Ratio 2.511
Quick Ratio 1.571
Cash Ratio 0.912

BMRN Profitability

Gross Margin 76.149
Operating Margin 8.037
Pretax Margin 7.794
Net Margin 6.929
Return on Assets 2.537
Return on Equity 3.509
Return on Total Capital 2.755
Return on Invested Capital 2.968

BMRN Capital Structure

Total Debt to Total Equity 22.899
Total Debt to Total Capital 18.633
Total Debt to Total Assets 16.573
Long-Term Debt to Equity 12.748
Long-Term Debt to Total Capital 10.373
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Biomarin Pharmaceutical Inc. - BMRN

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
1.84B 1.85B 2.05B 2.42B
Sales Growth
+9.25% +0.20% +10.91% +18.16%
Cost of Goods Sold (COGS) incl D&A
586.47M 532.45M 546.46M 577.07M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
105.88M 108.04M 101.97M 104.39M
Depreciation
43.68M 46.14M 39.17M 42.17M
Amortization of Intangibles
62.20M 61.90M 62.80M 62.21M
COGS Growth
+42.01% -9.21% +2.63% +5.60%
Gross Income
1.26B 1.31B 1.50B 1.84B
Gross Income Growth
-1.38% +4.60% +14.27% +22.74%
Gross Profit Margin
+68.17% +71.16% +73.31% +76.15%
2020 2021 2022 2023 5-year trend
SG&A Expense
1.36B 1.38B 1.49B 1.65B
Research & Development
628.12M 628.79M 649.61M 746.77M
Other SG&A
732.61M 756.18M 841.22M 901.13M
SGA Growth
-1.91% +1.78% +7.64% +10.54%
Other Operating Expense
- - - -
-
Unusual Expense
4.57M 9.55M 5.27M 20.71M
EBIT after Unusual Expense
(109.44M) (80.89M) 4.94M 173.73M
Non Operating Income/Expense
96.43M 20.87M 160.61M 32.16M
Non-Operating Interest Income
16.61M 10.48M 18.03M 58.34M
Equity in Earnings of Affiliates
- - - (6.00K)
-
Interest Expense
29.31M 15.34M 15.97M 17.34M
Interest Expense Growth
+24.93% -47.67% +4.13% +8.55%
Gross Interest Expense
29.31M 15.34M 15.97M 17.34M
Interest Capitalized
- - - -
-
Pretax Income
(42.32M) (75.35M) 149.58M 188.56M
Pretax Income Growth
+55.36% -78.04% +298.51% +26.07%
Pretax Margin
-2.30% -4.08% +7.31% +7.79%
Income Tax
(901.42M) (11.27M) 8.02M 20.92M
Income Tax - Current - Domestic
(13.56M) (699.00K) 17.86M 30.22M
Income Tax - Current - Foreign
1.04M 5.04M 42.25M 35.68M
Income Tax - Deferred - Domestic
(50.36M) (31.13M) (84.41M) (78.78M)
Income Tax - Deferred - Foreign
(838.55M) 15.52M 32.33M 33.80M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - (6.00K)
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
859.10M (64.08M) 141.56M 167.65M
Minority Interest Expense
- - - -
-
Net Income
859.10M (64.08M) 141.56M 167.65M
Net Income Growth
+3,702.40% -107.46% +320.91% +18.43%
Net Margin Growth
+46.63% -3.47% +6.91% +6.93%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
859.10M (64.08M) 141.56M 167.65M
Preferred Dividends
- - - -
-
Net Income Available to Common
859.10M (64.08M) 141.56M 167.65M
EPS (Basic)
4.7516 -0.3504 0.7641 0.8925
EPS (Basic) Growth
+3,667.27% -107.37% +318.07% +16.80%
Basic Shares Outstanding
180.80M 182.85M 185.27M 187.83M
EPS (Diluted)
4.5254 -0.3504 0.7492 0.875
EPS (Diluted) Growth
+3,497.45% -107.74% +313.81% +16.79%
Diluted Shares Outstanding
191.68M 182.85M 188.96M 191.59M
EBITDA
1.01M 36.70M 112.18M 298.83M
EBITDA Growth
+111.87% +3,533.66% +205.66% +166.38%
EBITDA Margin
+0.05% +1.99% +5.48% +12.35%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 95.962
Number of Ratings 30 Current Quarters Estimate 0.55
FY Report Date 12 / 2024 Current Year's Estimate 2.252
Last Quarter’s Earnings 0.55 Median PE on CY Estimate N/A
Year Ago Earnings 0.87 Next Fiscal Year Estimate 3.181
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 22 12 24 23
Mean Estimate 0.55 0.64 2.25 3.18
High Estimates 0.74 0.87 3.30 4.71
Low Estimate 0.43 0.44 1.85 1.81
Coefficient of Variance 14.34 22.69 19.31 23.31

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 18 17 18
OVERWEIGHT 5 5 3
HOLD 7 7 7
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Biomarin Pharmaceutical Inc. - BMRN

Date Name Shares Transaction Value
Jun 5, 2024 Elaine J. Heron Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 5, 2024 Richard A. Meier Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jun 5, 2024 Richard A. Meier Director 120,776 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $76.41 per share 9,228,494.16
Jun 5, 2024 Richard A. Meier Director 126,227 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $63.1 per share 7,964,923.70
Jun 5, 2024 Elaine J. Heron Director 97,720 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $76.41 per share 7,466,785.20
Jun 5, 2024 Elaine J. Heron Director 101,888 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $63.1 per share 6,429,132.80
May 31, 2024 George Eric Davis EVP, Chief Legal Officer 97,007 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $63.1 per share 6,121,141.70
May 31, 2024 George Eric Davis EVP, Chief Legal Officer N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
May 31, 2024 George Eric Davis EVP, Chief Legal Officer 56,157 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $75.29 per share 4,228,060.53
May 31, 2024 George Eric Davis EVP, Chief Legal Officer 58,936 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $74.46 per share 4,388,374.56
May 24, 2024 Robert J. Hombach Director 35,220 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 24, 2024 Elizabeth McKee Anderson Director 27,800 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 24, 2024 Willard H. Dere Director 32,300 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 24, 2024 Barbara W. Bodem Director 6,900 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 24, 2024 Mark Joseph Enyedy Director 6,900 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 24, 2024 Athena M. Countouriotis Director 6,900 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 24, 2024 May Kin Ho Director 21,360 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 24, 2024 David E. I. Pyott Director 49,750 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 23, 2024 Cristin Hubbard EVP, Chief Commercial Officer 19,390 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 23, 2024 Cristin Hubbard EVP, Chief Commercial Officer 14,690 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Biomarin Pharmaceutical Inc. in the News